Annabel Kartal Allen reports that Novo Nordisk’s blockbuster weight loss drug Wegovy (semaglutide) has received accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver scarring. This milestone makes it the first GLP-1 receptor agonist approved for this indication.
The approval stems from the Phase III ESSENCE trial, where Wegovy resolved steatohepatitis in 63% of patients compared with 34% on placebo and showed notable improvements in liver fibrosis. Full approval depends on ongoing trial data.